BioMedTracker will be offering numerous medical meeting conference planners through 2013-2014 for purchase a la carte, or in a bundle of several select conferences. For more information on conference availability and pricing, please email BioMedTracker or call BioMedTracker Client Services at (858) 200- 2357. The 2014 American College of Cardiology Annual Meeting will take place from March 28-March 31, 2014 in Washington, DC. We have assembled a broad pre-meeting planner listing presentation titles from the General Program, as well as listed the most relevant presentations/sessions (only abstract titles are currently available). Conference Highlight: PCSK9 Inhibitors The highlight of the conference is data from the PCSK9 inhibitors, particularly a large body of Phase III results from Amgen's evolocumab, which are included in late-breaking and featured clinical research presentations. Competitor alirocumab will also have monthly data from an early stage study, though in a poster. In addition, it was recently reported that the FDA is looking into cognitive side effects with this class of drugs, which is likely to be an area of significant interest, as well. There could be data on this, since Amgen has stated they did collect information on such adverse effects proactively. The planner gives a brief background on what to look for in the PCSK9 data and on the convenience of injection issue for evolocumab, though it is unclear whether further information will come out on the latter. It also highlights what the PCSK9 presentations are. Other Topics Another point of discussion at the conference is likely to be the new ACC/AHA lipid guidelines. The planner notes sessions on this change in approach that are likely to be interesting. There are several presentations on high–profile drug failures, which could have implications for further and ongoing development of those mechanisms. Finally, the planner provides a list of what we believe are the most relevant sessions and presentations of drug data, along with discussion of ongoing issues and controversies in the field. The latter include:

• Value of HDL as a target and whether there is any reason anymore to use niacin/fibrates.
• Value of treating triglycerides between 200-500 mg/dl. Uncertainty about this led to Vascepa's negative advisory committee panel in October.
• Treatment after ACS. Given antiplatelet Zontivity's positive advisory committee vote and likely approval in patients with a history of MI, it will be interesting to see opinions about it, though it failed its actual ACS trial.
• Heart failure with preserved ejection fraction and senile amyloidosis. Interesting given the development of novel therapies to treat amyloidosis (eg from ALNY).
• Is there any hope for further development of rhythm control in atrial fibrillation?
• Any hope for renal denervation?

To purchase the full conference planner in PDF and Excel, click the link at the top of the page. For our disclosures, please read the BioMedTracker Research Standards.